Questions selected by the ERS/ATS Severe Asthma Task Force
| Should a monoclonal anti-IL-5 antibody be used in adults and children# with severe asthma? |
| Should a measurement of a specific biomarker be used to guide initiation of treatment with a monoclonal anti-IL-5 or IL-5Rα antibody in adults and children with severe asthma? (Chosen biomarkers being FENO, peripheral or sputum eosinophils and serum periostin) |
| Should a measurement of a specific biomarker be used, in addition to total IgE level, to guide initiation of treatment with a monoclonal anti-IgE antibody in adults and children with severe asthma? (Chosen biomarkers being FENO, peripheral or sputum eosinophils and serum periostin) |
| Should an inhaled LAMA be used in adults and children with severe asthma? |
| Should a macrolide (i.e. azithromycin, clarithromycin) be used in adults and children with severe asthma? |
| Should a monoclonal anti-IL-4Rα be used in adults and children with severe asthma? |
R: receptor. #: for the purposes of this guideline, age >5 years. Reproduced and modified from [6].